Bionexus Gene Lab (BGLC) - 2023 Q2 - Quarterly Report

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the transition period from _____________ See accompanying notes to the condensed consolidated financial statements. ● our failure to comply with regulatory guidelines; ● general economic conditions and market conditions in the financial services industry; ● future sales of large blocks or our securities, which may adversely impact our share price; and The preceding list is not intended to be an exhaustive list o ...